The Food and Drug Administration today announced new efforts to spotlight situations where drugmakers may be pursuing “gaming tactics” to delay generic competition. “Today, we’re making public a list of companies that have potentially been blocking access to the samples of their branded products,” FDA Commissioner Scott Gottlieb, M.D., said in a statement. “We hope that this increased transparency will help reduce unnecessary hurdles to generic drug development and approval.” The information on the webpage includes, among other things, the brand drug company, the drug product and the number of inquiries FDA has received. “We’ll continue to look at more ways we can expand upon today’s action and call public attention to situations where the careful balance that Congress sought between product innovation and access may be being disrupted,” Gottlieb said.

Related News Articles

Perspective
Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress.
Headline
The AHA today voiced support for a Centers for Medicare…
Headline
The Centers for Medicare & Medicaid Services today issued a
Headline
The House of Representatives yesterday passed two bills that would prohibit health plans from restricting a pharmacist’s ability to inform enrollees when a…
Headline
The Senate last night voted 98-2 to approve the Patient Right to Know Drug Prices Act (S. 2554), a bill that would prohibit private health plans from…
Headline
A coalition of health care providers, insurers, seniors and others is pushing back on some of the latest claims by the Pharmaceutical Research and…